Morrison Foerster advised Carlsmed, a commercial-stage medical technology company pioneering AI-enabled personalized spine surgery solutions, on its $100.5 million initial public offering (IPO). The IPO was for 6,700,000 shares of common stock at price to the public of $15.00 per share. Carlsmed’s common stock began trading on the Nasdaq Global Select Market on July 23, 2025 under the ticker symbol “CARL.” BofA Securities, Goldman Sachs & Co. LLC, and Piper Sandler acted as joint lead book-running managers for the IPO. Truist Securities and BTIG acted as joint book-runners for the IPO.
The MoFo team was led by Austin capital markets partner John Hensley, San Diego capital markets partner Tommy Felix, and emerging companies + venture capital partner Jim Krenn, with New York capital markets associates Carolina Bernal-Ramirez and Devansi Reshamwala, Austin capital markets associate Eric Harper and San Diego corporate associates Bryce Bark and Carlisle Olsen.